ECSP077426A - USO DE UN INHIBIDOR DE mTOR EN EL TRATAMIENTO DE LEIOMIOMA UTERINO - Google Patents

USO DE UN INHIBIDOR DE mTOR EN EL TRATAMIENTO DE LEIOMIOMA UTERINO

Info

Publication number
ECSP077426A
ECSP077426A EC2007007426A ECSP077426A ECSP077426A EC SP077426 A ECSP077426 A EC SP077426A EC 2007007426 A EC2007007426 A EC 2007007426A EC SP077426 A ECSP077426 A EC SP077426A EC SP077426 A ECSP077426 A EC SP077426A
Authority
EC
Ecuador
Prior art keywords
treatment
leiomioma
uterine
mtor inhibitor
mtor
Prior art date
Application number
EC2007007426A
Other languages
English (en)
Inventor
Robert R Ruffolo Jr
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP077426A publication Critical patent/ECSP077426A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Esta invención provee para el uso de un inhibidor mTOR en el tratamiento o inhibición de fibroides.
EC2007007426A 2004-10-28 2007-04-27 USO DE UN INHIBIDOR DE mTOR EN EL TRATAMIENTO DE LEIOMIOMA UTERINO ECSP077426A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62291704P 2004-10-28 2004-10-28

Publications (1)

Publication Number Publication Date
ECSP077426A true ECSP077426A (es) 2007-05-30

Family

ID=35768583

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007426A ECSP077426A (es) 2004-10-28 2007-04-27 USO DE UN INHIBIDOR DE mTOR EN EL TRATAMIENTO DE LEIOMIOMA UTERINO

Country Status (17)

Country Link
US (1) US7528145B2 (es)
EP (1) EP1804779A1 (es)
JP (1) JP2008518966A (es)
KR (1) KR20070070184A (es)
CN (1) CN101048152A (es)
AU (1) AU2005302004A1 (es)
BR (1) BRPI0518079A (es)
CA (1) CA2585840A1 (es)
CR (1) CR9068A (es)
EC (1) ECSP077426A (es)
IL (1) IL182748A0 (es)
MX (1) MX2007005153A (es)
NI (1) NI200700111A (es)
NO (1) NO20071926L (es)
RU (1) RU2007112787A (es)
WO (1) WO2006050461A1 (es)
ZA (1) ZA200703446B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003210787B2 (en) 2002-02-01 2009-04-23 Medinol Ltd. Phosphorus-containing compounds & uses thereof
CN101583347A (zh) * 2006-11-14 2009-11-18 阿里亚德医药股份有限公司 口服制剂
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
WO2009131631A1 (en) * 2008-04-14 2009-10-29 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
EP2965763B8 (en) * 2009-04-10 2018-08-15 Haiyan Qi Anti-aging agents
EP2763985B1 (en) * 2011-10-07 2016-06-22 Cellzome Limited {(4-(4-morpholino-dihydrothieno[3,4-d]pyrimidin-2-yl)aryl}urea or carbamate derivatives as mtor inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5023262A (en) * 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
AU1074897A (en) 1995-11-08 1997-05-29 University Of South Florida Guinea pig model for leiomyomas and atherosclerosis
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
EA200000087A1 (ru) * 1997-07-01 2000-08-28 Атеродженикс, Инк. Повышение эффективности терапии гиперпролиферативных состояний с помощью антиоксиданта
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
JP2000012799A (ja) * 1998-06-25 2000-01-14 Nec Ic Microcomput Syst Ltd 半導体メモリ装置とその製造方法
DE60010098T2 (de) 1999-08-24 2005-03-31 Ariad Gene Therapeutics, Inc., Cambridge 28-epirapaloge
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
AU2001283139A1 (en) * 2000-08-11 2002-02-25 Wyeth Method of treating estrogen receptor positive carcinoma
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US20030144204A1 (en) * 2001-12-19 2003-07-31 Baylor College Of Medicine Akt-based inducible survival switch
UA82328C2 (uk) 2002-07-30 2008-04-10 Уайт Парентеральна композиція на основі гідроксіестеру рапаміцину (варіанти) та спосіб її приготування
WO2004014222A2 (en) * 2002-08-12 2004-02-19 The Regents Of The University Of Michigan Diagnosis and treatment of tuberous sclerosis
DK1635830T3 (da) 2002-09-17 2009-02-23 Wyeth Corp Granulatformulering af rapamycinesteren CCI-779
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
AR043504A1 (es) * 2003-03-17 2005-08-03 Novartis Ag Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
WO2005016935A2 (en) 2003-08-07 2005-02-24 Wyeth Regioselective synthesis of cci-779

Also Published As

Publication number Publication date
BRPI0518079A (pt) 2008-11-04
AU2005302004A1 (en) 2006-05-11
WO2006050461A1 (en) 2006-05-11
EP1804779A1 (en) 2007-07-11
RU2007112787A (ru) 2008-12-10
JP2008518966A (ja) 2008-06-05
NI200700111A (es) 2008-01-17
US7528145B2 (en) 2009-05-05
ZA200703446B (en) 2010-10-27
KR20070070184A (ko) 2007-07-03
CR9068A (es) 2007-10-01
CA2585840A1 (en) 2006-05-11
NO20071926L (no) 2007-05-24
CN101048152A (zh) 2007-10-03
IL182748A0 (en) 2007-09-20
MX2007005153A (es) 2007-06-26
US20060094745A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
ECSP077426A (es) USO DE UN INHIBIDOR DE mTOR EN EL TRATAMIENTO DE LEIOMIOMA UTERINO
ECSP056001A (es) Combinaciones antineoplásicas
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
CR8888A (es) Indazoles utiles en el tratamiento de enfermedades cardiovasculares
ECSP066635A (es) Quinolinas utiles en el tratamiento de enfermedades cardiovasculares
SV2008002477A (es) Combinacion para terapia de hiperplasia benigna de prostata ref. bhc051038-sv
DE502005004171D1 (de) Verstelleinrichtung für Triggerschalter
WO2007067976A3 (en) Method of using il6 antagonists with proteasome inhibitors
ATE507227T1 (de) Kondensierte bicyclische mtor-inhibitoren
ECSP056114A (es) Combinaciones antineoplásicas
SG148179A1 (en) Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
BRPI0515319A (pt) análogos de quinolona
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
CL2007002388A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas.
UY29774A1 (es) Inhibidor de atm
CR9257A (es) Polimorfo cci-779 y uso del mismo
SE0301650D0 (sv) Novel compounds
CL2011000100A1 (es) Uso de un inhibidor de desacetilasa de histona para el tratamiento de la enfermedad de hodgkin.
AR064214A1 (es) Uso de epotilonas en el tratamiento de la osteoporosis y enfermedades relacionadas
DOP2004000935A (es) Cocinar? nuevo uso para el autoclave
CL2008001363A1 (es) Uso de un inhibidor de desacetilasa de histona para el tratamiento de melanoma.
CL2007002391A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de fibrosis.
ITGE20040093A1 (it) Dispositivo flessibile per lo scarico di acque grigie.
ES1053334Y (es) Dispositivo manual para el calculo de restas.
ES1055870Y (es) Dispositivo de iluminacion para un panel de instrumentos.